VRCA / Verrica Pharmaceuticals Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Second Amendment to Collaboration and License Agreement, dated as of June 27, 2025, by and between the Company and Torii Pharmaceuticals Co., Ltd.

Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE DESIGNATED [***]. Execution Copy SECOND AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT This Second Amendment to the Collaboration and License Agreement (the “Second Amendment”) is entered

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results – Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million

EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results – Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue from Torii Pharmaceutical – – Completed Successful End of Phase 2 Meeting for VP-315 for Basal Cell Carcino

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Verrica Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commis

Sixth Amendment and Waiver to Credit Agreement dated as of June 10, 2025, by and between the Company and OrbiMed Royalty & Credit Opportunities IV, LP.

Exhibit 10.1 Sixth Amendment and Waiver to Credit Agreement This SIXTH AMENDMENT AND WAIVER TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of June 10, 2025 by and among VERRICA PHARMACEUTICALS INC., a Delaware corporation (the “Borrower”), the Lenders party hereto (the “Lenders”), and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as administrative agent for the Lenders (togeth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 Verrica Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 Verrica Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

Certificate of Amendment of the Amended and Restated Certificate of Incorporation

EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VERRICA PHARMACEUTICALS INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Verrica Pharmaceuticals Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “Ge

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 Verrica Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts – Verrica to receive a $8 million mileston

EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts – Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule – – Verrica to receive a $10 million milest

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 Verrica Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Verrica Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissi

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissi

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results – Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company hist

Exhibit 99.1 Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results – Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4’24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Dr

Power of Attorney (included on the signature page of this Form S-8).

S-8 As filed with the Securities and Exchange Commission on May 13, 2025 Registration No.

Waiver, dated February 18, 2025, by and between the Company and Orbimed Royalty & Credit Opportunities IV, LP.

Exhibit 10.2 WAIVER This WAIVER (this “Waiver”) is made and entered into as of February 18, 2025 by and among VERRICA PHARMACEUTICALS INC., a Delaware corporation (the “Borrower”), the Lenders party hereto (the “Lenders”), and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as administrative agent for the Lenders (together with its Affiliates, successors, transferees and assignees, the “Administrat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commis

Release Agreement, dated April 24, 2025, by and between the Company and Christopher G. Hayes

Exhibit 10.1 Release Agreement This Release Agreement (“Release” or “Agreement”) is made by and between Christopher G. Hayes (“you”) and Verrica Pharmaceuticals Inc. (the “Company”). A copy of this Release is an attachment to the Employment Agreement between the Company and you dated February 27, 2020 (the “Employment Agreement”). Capitalized terms not defined in this Agreement carry the definitio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commis

VERRICA PHARMACEUTICALS INC. 44 W. Gay St., Suite 400 West Chester, PA, 19380

VERRICA PHARMACEUTICALS INC. 44 W. Gay St., Suite 400 West Chester, PA, 19380 March 21, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jason Drory Re: Verrica Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-285719) Request for Acceleration of Effective Date Ladies and Gentlemen: In accorda

Registrant’s Insider Trading Policy

Exhibit 19.1 Verrica PHARMACEUTICALS INC. Insider Trading Policy As Amended and Restated on March 10, 2025 I. Introduction This policy determines acceptable transactions in the securities of Verrica Pharmaceuticals Inc. (the “Company”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important informati

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Verrica Pharmaceuticals Inc.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commis

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results – Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses – – Com

Exhibit 99.1 Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results – Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses – – Company reports positive quarterly revenue earlier than previously disclosed expectations, as new demand resulted in Company’s primary distr

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.5 VERRICA PHARMACEUTICALS INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF VERRICA PHARMACEUTICALS INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VERRICA PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Form of Indenture, between the Registrant and one or more trustees to be named.

Exhibit 4.2 VERRICA PHARMACEUTICALS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 2 Section 2.01 Designation and Terms of Securities 2 Section 2.02 Form of Securities and Trustee’s Certificate

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.6 Verrica Pharmaceuticals Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of VERRICA PHARMACEUTICALS INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VERRICA PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] o

As filed with the Securities and Exchange Commission on March 11, 2025

Table of Contents As filed with the Securities and Exchange Commission on March 11, 2025 Registration No.

Form of Common Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.4 VERRICA PHARMACEUTICALS INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF VERRICA PHARMACEUTICALS INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VERRICA PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Com

JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k)

EX-99.1 CHARTER 2 p25-0229exhibit99.htm EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Comm

Offer Letter, dated December 5, 2024, by and between the Company and David Zawitz

Exhibit 10.1 December 5, 2024 David Zawitz Re: Employment Terms Dear David: Verrica Pharmaceuticals, Inc. (the “Company”) is pleased to offer you employment beginning on December 9, 2024 or such other date as set by the Company in its discretion (the “Start Date”). Position Your position will be Chief Operating Officer, responsible for performing duties regularly associated with your position and

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Verrica Pharmaceuticals Inc.

Amendment to 2024 Inducement Plan

Exhibit 10.2 AMENDMENT TO VERRICA PHARMACEUTICALS INC. 2024 INDUCEMENT PLAN A. Verrica Pharmaceuticals Inc., a corporation organized under the laws of the State of Delaware, (the “Company”) established the Company’s 2024 Inducement Plan (the “Plan”); B. The Plan currently provides for 2,000,000 shares of Common Stock to be reserved for issuance under the Plan; and C. The Company now wishes to amen

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Comm

VRCA / Verrica Pharmaceuticals Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d911102dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92511W108 (CUSIP Number) December 5, 2024 (Date of Event Which Requires Filing of this Stateme

As filed with the Securities and Exchange Commission on December 9, 2024

S-8 As filed with the Securities and Exchange Commission on December 9, 2024 Registration No.

VRCA / Verrica Pharmaceuticals Inc. / Manning Paul B - SC 13D/A Activist Investment

SC 13D/A 1 tm2429593d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92511W108 (CUSIP Number) Paul B. Manning c/o PBM Capital Group, LLC 200 Garrett Street, Sui

Form of Series A Warrant.

Exhibit 4.2 SERIES A WARRANT TO PURCHASE COMMON STOCK VERRICA PHARMACEUTICALS INC. Warrant Shares: [ ] Issue Date: [], 2024 THIS SERIES A WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Iss

44,964,045 Shares of Common Stock Pre-Funded Warrants to Purchase 2,235,955 Shares of Common Stock Series A Warrants to Purchase 23,600,000 Shares of Common Stock (or Pre-Funded Warrants) Series B Warrants to Purchase 23,600,000 Shares of Common Stoc

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268229 PROSPECTUS SUPPLEMENT (To Prospectus Dated December 19, 2022) 44,964,045 Shares of Common Stock Pre-Funded Warrants to Purchase 2,235,955 Shares of Common Stock Series A Warrants to Purchase 23,600,000 Shares of Common Stock (or Pre-Funded Warrants) Series B Warrants to Purchase 23,600,000 Shares of Common Stock (or Pre

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Com

Verrica Announces Pricing of $42.0 Million Public Offering

Exhibit 99.1 Verrica Announces Pricing of $42.0 Million Public Offering WEST CHESTER, PA – November 21, 2024 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of it

Form of Pre-Funded Warrant.

Exhibit 4.1 VERRICA PHARMACEUTICALS INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: November [ ], 2024 Verrica Pharmaceuticals Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted

Form of Series B Warrant.

Exhibit 4.3 SERIES B WARRANT TO PURCHASE COMMON STOCK VERRICA PHARMACEUTICALS INC. Warrant Shares: [ ] Issue Date: [], 2024 THIS SERIES B WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Iss

Underwriting Agreement, dated November 20, 2024, by and between the Company and Jefferies LLC.

Exhibit 1.1 VERRICA PHARMACEUTICALS INC. (a Delaware corporation) 44,964,045 Shares of Common Stock Warrants to Purchase 47,200,000 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof) Pre-Funded Warrants to Purchase 2,235,955 Shares of Common Stock UNDERWRITING AGREEMENT Dated: November 20, 2024 Verrica Pharmaceuticals Inc. (a Delaware corporation) 44,964,045 Shares of Common Stock War

We are a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. We are primarily focused on developing clinician administered therapies in areas of high unmet need. Our current product po

Exhibit 99.2 Overview We are a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. We are primarily focused on developing clinician administered therapies in areas of high unmet need. Our current product portfolio consists of one approved product with several potential follow-on indications, as well as two additional pipeline produc

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Com

Subject to Completion, dated November 20, 2024

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268229 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell the securities and are not soliciting an offer to buy the securities in any jurisdiction where the offer or sale is not permitted.

Verrica Announces Proposed Public Offering

Exhibit 99.1 Verrica Announces Proposed Public Offering WEST CHESTER, PA – November 20, 2024 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to p

VRCA / Verrica Pharmaceuticals Inc. / Avoro Capital Advisors LLC - VERRICA PHARMACEUTICALS INC. Passive Investment

SC 13G/A 1 p24-3029sc13ga.htm VERRICA PHARMACEUTICALS INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92511W108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Verrica Pharmaceuticals Inc.

As filed with the Securities and Exchange Commission on November 6, 2024

As filed with the Securities and Exchange Commission on November 6, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Fifth Amendment to Credit Agreement, dated as of August 2, 2024, by and between the Registrant and OrbiMed Royalty & Credit Opportunities IV, LP.

EXHIBIT 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE DESIGNATED [***]. Execution Version Fifth AMENDMENT and Waiver TO CREDIT AGREEMENT This FIFTH AMENDMENT AND WAIVER TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of August 2,

Release and Consulting Agreement, dated as of August 30, 2024, by and between the Registrant and Joseph Bonaccorso

EXHIBIT 10.2 Execution Version Release Agreement This Release Agreement (“Release” or “Agreement”) is made by and between Joseph Bonaccorso (“you”) and Verrica Pharmaceuticals Inc. (the “Company”). 1. Separation. The Company and you agree and acknowledge that you have provided notice to the Company of your resignation from employment with the Company effective August 30, 2024. As such, your last d

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition – Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a

Exhibit 99.1 Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition – Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed appl

Release Agreement, dated as of November 4, 2024, by and between the Registrant and Ted White (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38529), filed with the Securities and Exchange Commission on November 4, 2024).

EX-10.1 Exhibit 10.1 Release Agreement This Release Agreement (“Release” or ”Agreement”) is made by and between Ted White (“you”) and Verrica Pharmaceuticals Inc. (the ”Company”). A copy of this Release is an attachment to the Amended and Restated Employment Agreement between the Company and you dated January 10, 2020 (the ”Employment Agreement”). Capitalized terms not defined in this Agreement ca

Form of Stock Option Grant Notice and Stock Option Agreement under 2024 Inducement Plan.

EX-10.6 Exhibit 10.6 VERRICA PHARMACEUTICALS INC. STOCK OPTION GRANT NOTICE (2024 INDUCEMENT PLAN) Verrica Pharmaceuticals Inc. (the “Company”), pursuant to its 2024 Inducement Plan, as may be amended from time to time (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below as an inducement material to Optionholder enteri

Offer Letter, dated as of November 4, 2024, by and between the Registrant and Jayson Rieger (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-38529), filed with the Securities and Exchange Commission on November 4, 2024).

EX-10.2 Exhibit 10.2 November 4, 2024 Jayson Rieger Re: Employment Terms Dear Jayson: Verrica Pharmaceuticals, Inc. (the “Company”) is pleased to offer you employment beginning on November 5, 2024 or such other date as set by the Company in its discretion (the “Start Date”). Position; Board Role Your position will be President and Chief Executive Officer (the “CEO”), responsible for performing dut

Verrica Pharmaceuticals, Inc. 2024 Inducement Plan.

EX-10.4 Exhibit 10.4 VERRICA PHARMACEUTICALS INC. 2024 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: NOVEMBER 1, 2024 1.  GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance und

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 Verrica Pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Comm

Form of Restricted Stock Unit Award Grant Notice and Award Agreement under 2024 Inducement Plan.

EX-10.5 Exhibit 10.5 VERRICA PHARMACEUTICALS INC. RESTRICTED STOCK UNIT GRANT NOTICE (2024 INDUCEMENT PLAN) Verrica Pharmaceuticals Inc. (the “Company”), pursuant to its 2024 Inducement Plan, as may be amended from time to time (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (

Professional Services Agreement, dated November 4, 2024, by and between the Company and John J. Kirby

EX-10.3 Exhibit 10.3 PROFESSIONAL SERVICES AGREEMENT This Professional Services Agreement (the “Agreement”), effective as of November 5, 2024 (the “Effective Date”), is made between Verrica Pharmaceuticals Inc., located at 44 W. Gay St., Suite 400, West Chester, PA 19380 (the “Company”) and John J. Kirby (“Kirby”). Company and Kirby, collectively, are the “Parties”, and each a “Party”. RECITALS WH

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Co

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 Verrica Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Verrica Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commi

Warrant to Purchase Common Stock, dated as of May 14, 2024, by and between the Registrant and Torii Pharmaceuticals Co., Ltd.

exhibit 4.1 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE TERMS OF THIS WARRANT, THE ACT A

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results – Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH’s distribution footprint to include Cencora, Inc. as a specialty distributor –

Exhibit 99.1 Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results – Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH’s distribution footprint to include Cencora, Inc. as a specialty distributor – – Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carci

First Amendment to Collaboration and License Agreement, dated as of May 14, 2024, by and between the Registrant and Torii Pharmaceuticals Co., Ltd.

EXHIBIT 10.4 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE DESIGNATED [***]. Execution Version FIRST AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT This First Amendment to the Collaboration and License Agreement (the “First Amendment”) is entered

Third Amendment to Credit Agreement, dated as of May 6, 2024, by and between the Registrant and OrbiMed Royalty & Credit Opportunities IV, LP.

EXHIBIT 10.1 Execution Version Third AMENDMENT and Waiver TO CREDIT AGREEMENT This THIRD AMENDMENT AND WAIVER TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of May 6, 2024 by and among VERRICA PHARMACEUTICALS INC., a Delaware corporation (the “Borrower”), the Lenders party hereto (the “Lenders”), and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as administrative agent for the

Fifth Amendment to Credit Agreement, dated as of August 2, 2024, by and between the Registrant and OrbiMed Royalty & Credit Opportunities IV, LP.

EXHIBIT 10.3 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE DESIGNATED [***]. Execution Version Fifth AMENDMENT and Waiver TO CREDIT AGREEMENT This FIFTH AMENDMENT AND WAIVER TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of August 2,

Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal estimates and

Company Overview August 2024 Exhibit 99.2 Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal estimates and research. While Verrica believes these third-party sources to be reliable as of the date of this presentatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Fourth Amendment to Credit Agreement, dated as of June 26, 2024, by and between the Registrant and OrbiMed Royalty & Credit Opportunities IV, LP.

EXHIBIT 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE DESIGNATED [***]. Execution Version FOURTH AMENDMENT TO CREDIT AGREEMENT This FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of June 26, 2024 by and among VE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 Verrica Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commis

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Verrica Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissi

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissi

Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts Global pivotal Phase 3 cl

Exhibit 99.1 Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025 Amendment sh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissi

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Verrica Pharmaceuticals Inc.

As filed with the Securities and Exchange Commission on May 13, 2024

As filed with the Securities and Exchange Commission on May 13, 2024 Registration No.

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results – Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee p

Exhibit 99.1 Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results – Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma (BCC) expected in the second quarter of 2024 – –

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Prox

Second Amendment to Credit Agreement, dated as of January 31, 2024, by and between the Registrant and Orbimed Royalty & Credit Opportunities IV, LP.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

35 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

35 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

First Amendment to Credit Agreement, dated as of December 20, 2023, by and between the Registrant and Orbimed Royalty & Credit Opportunities IV, LP

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Com

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results – Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and managed Medicaid

EX-99.1 EXHIBIT 99.1 Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results – Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, PA –Feb 29, 2024 (GLOBE NEWSWIRE) – Verrica Pharmace

Second Amended and Restated Non-Employee Director Compensation Policy, adopted by the Board as of February 27, 2024

Exhibit 10.21 VERRICA PHARMACEUTICALS INC. Second Amended and Restated Non-Employee Director Compensation Policy As adopted by the Board on February 27, 2024 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Verrica Pharmaceuticals Inc. (the “Company”) and is not affiliated with an entity that beneficially owns 5% or more of the Company’s outstanding sha

Incentive Compensation Recoupment Policy

Exhibit 97 Verrica Pharmaceuticals Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Verrica Pharmaceuticals Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment

AGREEMENT

EX-99.1 2 d705788dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2

VRCA / Verrica Pharmaceuticals Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d705788dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92511W108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statem

VRCA / Verrica Pharmaceuticals Inc. / Avoro Capital Advisors LLC - VERRICA PHARMACEUTICALS INC. Passive Investment

SC 13G 1 p24-0700sc13g.htm VERRICA PHARMACEUTICALS INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92511W108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Verrica Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commi

Not For Promotional Use Disclaimer Certain information contained in this presentation and statements made orally during Although we believe the expectations reflected in such forward-looking statements are this presentation relates to or is based on

Exhibit 99.1 Company Overview January 2024 Copyright © 2024 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use Disclaimer Certain information contained in this presentation and statements made orally during Although we believe the expectations reflected in such forward-looking statements are this presentation relates to or is based on studies, publications, surveys and other dat

Credit Agreement, dated as of July 26, 2023, by and between the Registrant and Orbimed Royalty & Credit Opportunities IV, LP (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38529), filed with the Securities and Exchange Commission on November 9, 2023).

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) is the type that the registrant treats as private or confidential. OMISSIONS ARE DESIGNATED [***]. CREDIT AGREEMENT dated as of July 26, 2023 among VERRICA PHARMACEUTICALS INC., as the Borrower, ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as the Initial Lender and Adminis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Warrant Certificate, dated as of July 26, 2023, by and between the Registrant and Orbimed Royalty & Credit Opportunities IV, LP (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38529), filed with the Securities and Exchange Commission on November 9, 2023)

Execution Version Exhibit 10.3 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Comm

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results – Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians – – Over 112 million lives covered to date on commercial insurance and managed Medicaid

Exhibit 99.1 Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results – Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians – – Over 112 million lives covered to date on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, PA – Nov 9, 2023 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals

Pledge and Security Agreement, dated as of July 26, 2023, by and between the Registrant and Orbimed Royalty & Credit Opportunities IV, LP (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38529), filed with the Securities and Exchange Commission on November 9, 2023).

Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) is the type that the registrant treats as private or confidential. OMISSIONS ARE DESIGNATED [***]. PLEDGE AND SECURITY AGREEMENT This PLEDGE AND SECURITY AGREEMENT, dated as of July 26, 2023 (as amended, supplemented or otherwise modified from time to time, this “Security Ag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results – In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, pri

EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results – In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – – YCANTH™ launch expected by September 2023 – – Expanding Part 2 enrollment of ongoing Phase 2 trial of VP-315

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Verrica Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commis

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal est

EX-99.1 Company Overview July 2023 Copyright © 2023 Verrica Pharmaceuticals. All rights reserved. Exhibit 99.1 Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal estimates and research. While Verrica beli

Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed – Verrica received $50M upon the close of the transaction; $75M of additional capital available in tranches based on the achievement of certain revenue milestones –

EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed – Verrica received $50M upon the close of the transaction; $75M of additional capital available in tranches based on the achievement of certain revenue milestones – – Proceeds from the transaction to support the commercialization of YCANTH™, which was approved by the FDA on July 21, 2023, for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 Verrica Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

Verrica Pharmaceuticals Announces FDA Approval of YCANTH

EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum – Molluscum, is a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – – YCANTH™ is a drug-device combination produc

Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET – Te

EX-99.3 Exhibit 99.3 Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET – Term loan facility would provide for up to $125M in non-dilutive capital; $50M immediately available to Company following close of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 Verrica Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal est

EX-99.2 YCANTH™ (cantharidin, 0.7%) FDA Approval Call July 24, 2023 Copyright © 2023 Verrica Pharmaceuticals. All rights reserved. Exhibit 99.2 Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal estimates

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Verrica Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissi

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 - Potential to Become Only FDA-approved Therapy for Treatment of Molluscum Contagiosum Raised Gross Procee

EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 - Potential to Become Only FDA-approved Therapy for Treatment of Molluscum Contagiosum Raised Gross Proceeds of $32.5 Million in February 2023 in an Underwritten Offering VP-315 Advanced into Part 2 of Phase 2 Trial in Basal Cell Carci

As filed with the Securities and Exchange Commission on May 9, 2023

S-8 As filed with the Securities and Exchange Commission on May 9, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Verrica Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Verrica Pharmaceuticals Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

35 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

35 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 Verrica Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results New Drug Application for VP-102 assigned PDUFA goal date of July 23, 2023 VP-102 has potential to address the approximately six million patients in the U.S. with moll

EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results New Drug Application for VP-102 assigned PDUFA goal date of July 23, 2023 VP-102 has potential to address the approximately six million patients in the U.S. with molluscum contagiosum Dosing of first patient in Part 2 of Phase 2 study of VP-315 for treatment of basal cell carcinoma expected in

750,000 Shares of Common Stock Pre-Funded Warrants to Purchase 4,064,814 Shares of Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268229 PROSPECTUS SUPPLEMENT (To Prospectus Dated December 19, 2022) 750,000 Shares of Common Stock Pre-Funded Warrants to Purchase 4,064,814 Shares of Common Stock We are offering 750,000 shares of our common stock at a purchase price of $6.75 per share and, in lieu of offering shares of our common stock to certain inve

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Verrica Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Verrica Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38529 46-3137900 (State or other jurisdiction of incorporation) (Com

Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

EX-99.1 Exhibit 99.1 Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants WEST CHESTER, Pa., February 21, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of its underwritten offeri

Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38529), filed with the Securities and Exchange Commission on February 21, 2023).

EX-4.1 Exhibit 4.1 VERRICA PHARMACEUTICALS INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: February [], 2023 Verrica Pharmaceuticals Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its perm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Verrica Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Com

1

Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated February 21, 2023 Relating to Prospectus Dated December 19, 2022 Registration Statement No.

Underwriting Agreement, dated February 21, 2023, by and between the Company and Jefferies LLC.

EX-1.1 Exhibit 1.1 VERRICA PHARMACEUTICALS INC. (a Delaware corporation) 750,000 Shares of Common Stock Pre-Funded Warrants to Purchase 4,064,814 Shares of Common Stock UNDERWRITING AGREEMENT Dated: February 21, 2023 Verrica Pharmaceuticals Inc. (a Delaware corporation) 750,000 Shares of Common Stock Pre-Funded Warrants to Purchase 4,064,814 Shares of Common Stock UNDERWRITING AGREEMENT February 2

VRCA / Verrica Pharmaceuticals Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92511W108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

AGREEMENT

EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2023 PERCEPTIVE ADVISORS LLC

Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal est

EX-99.1 Company Overview February 2023 Copyright © 2023 Verrica Pharmaceuticals. All rights reserved. Exhibit 99.1 Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal estimates and research. While Verrica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 Verrica Pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Verrica Pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Comm

Up to $50,000,000 Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268229 PROSPECTUS Up to $50,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, under this prospectus, we may offer and s

December 15, 2022

December 15, 2022 VIA EDGAR Ada D. Sarmento U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Verrica Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-268229) Request for Acceleration of Effective Date Acceleration Request Requested Date: Monday, December 19, 2022 Requested Time: 8:00 a.m. Eastern Time Dear Ms

Cooley LLP Reston Town Center 11951 Freedom Drive 14th Floor Reston, VA 20190-5656 t: +1 703 456 8000 f: +1 703 456 8100 cooley.com

CORRESP 1 filename1.htm Mark Ballantyne T: +1 703 456 8084 [email protected] VIA EDGAR November 18, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Lynn Dicker Kevin Kuhar Re: Verrica Pharmaceuticals Inc. Form 10-K for the fiscal year ended December 31, 2021 Filed March 2, 2022 File No. 001-3852

As filed with the Securities and Exchange Commission on November 7, 2022

Table of Contents As filed with the Securities and Exchange Commission on November 7, 2022 Registration No.

Form of Common Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.4 VERRICA PHARMACEUTICALS INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF VERRICA PHARMACEUTICALS INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between VERRICA PHARMACEUTICALS INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.5 VERRICA PHARMACEUTICALS INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF VERRICA PHARMACEUTICALS INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between VERRICA PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association]

Form of Indenture, between the Registrant and one or more trustees to be named.

Exhibit 4.2 VERICA PHARMACEUTICALS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certificate 6

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Comm

Open Market Sale AgreementSM between the Registrant and Jefferies LLC, dated November 7, 2022 (incorporated herein by reference to Exhibit 1.2 to the Registrant’s Registration Statement on Form S-3 (File No. 333-268229), filed with the Securities and Exchange Commission on November 7, 2022).

EX-1.2 2 d418490dex12.htm EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM November 7, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Verrica Pharmaceuticals Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “A

Filing Fee Table

EX-FILING FEES 9 d418490dexfilingfees.htm EX107 Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (a) Proposed Maximum Offering Price Per Unit Maximum Agg

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.6 VERRICA PHARMACEUTICALS INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF VERRICA PHARMACEUTICALS INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between VERRICA PHARMACEUTICALS INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] o

Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results Reiterates expectation to resubmit NDA for VP-102 for Molluscum Contagiosum in Q1 2023 Part 1 of Phase 2 for VP-LTX-315 for Basal Cell Carcinoma on track to conclude Q1 2023

EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results Reiterates expectation to resubmit NDA for VP-102 for Molluscum Contagiosum in Q1 2023 Part 1 of Phase 2 for VP-LTX-315 for Basal Cell Carcinoma on track to conclude Q1 2023 WEST CHESTER, PA – November 7, 2022 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics

Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal est

Company Overview September 14, 2022 Copyright ? 2022 Verrica Pharmaceuticals. All rights reserved. Exhibit 99.1 Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica?s own internal estimates and research. While Verrica bel

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Co

Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of molluscum contagiosum Ver

Exhibit 99.1 Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of molluscum contagiosum Verrica has begun working with Piramal Pharma Solutions for production of bulk solution and reaffirms plans to resubmit NDA for VP-102 for m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commi

VRCA / Verrica Pharmaceuticals Inc / Manning Paul B - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92511W108 (CUSIP Number) Paul B. Manning c/o PBM Capital Group, LLC 200 Garrett Street, Suite S Charlottesville, VA 22902 (434) 980-8100

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

12,000,000 Shares Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-237171 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 25, 2020) 12,000,000 Shares Common Stock We are offering 12,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol ?VRCA.? The last reported sale price of our common stock on The Nasdaq Global Market on June 29, 2022 wa

Underwriting Agreement by and between Verrica Pharmaceuticals Inc. and RBC Capital Markets, LLC, dated June 29, 2022.

EX-1.1 2 d358140dex11.htm EX-1.1 Exhibit 1.1 Execution Version VERRICA PHARMACEUTICALS INC. (a Delaware corporation) 12,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: June 29, 2022 Verrica Pharmaceuticals Inc. (a Delaware corporation) 12,000,000 Shares of Common Stock UNDERWRITING AGREEMENT June 29, 2022 RBC Capital Markets, LLC 200 Vesey Street New York, New York 10281 Ladies and Ge

Verrica Announces Proposed Public Offering of Common Stock

Exhibit 99.1 Verrica Announces Proposed Public Offering of Common Stock West Chester, Pa., June 29, 2022 (GLOBE NEWSWIRE) ? Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwri

Verrica Announces Pricing of Public Offering of Common Stock

Exhibit 99.2 Verrica Announces Pricing of Public Offering of Common Stock WEST CHESTER, Pa., June 29, 2022 (GLOBE NEWSWIRE) ? Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of its underwritten public offering of 12,000,000 shares of its common stock at a

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 Verrica Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38529 46-3137900 (State or other jurisdiction of incorporation) (Commiss

SUBJECT TO COMPLETION, DATED JUNE 29, 2022

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-237171 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissi

Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissi

Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results Upcoming PDUFA date of May 24, 2022 for VP-102 NDA for the treatment of molluscum First patient dosed in Phase 2 trial of LTX-315 in basal cell carcinoma

Exhibit 99.1 Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results Upcoming PDUFA date of May 24, 2022 for VP-102 NDA for the treatment of molluscum First patient dosed in Phase 2 trial of LTX-315 in basal cell carcinoma WEST CHESTER, PA ? May 9, 2022 (GLOBE NEWSWIRE) ? Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissio

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Verrica Pharmaceuticals Inc.

As filed with the Securities and Exchange Commission on May 9, 2022

As filed with the Securities and Exchange Commission on May 9, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 d221989ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

Definitive Proxy Statement

DEF 14A 1 d221989ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as

Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal est

Company Overview April 7, 2022 Copyright ? 2022 Verrica Pharmaceuticals. All rights reserved. Exhibit 99.1 Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica?s own internal estimates and research. While Verrica believes

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

Waiver and Second Amendment to Loan and Security Agreement, dated as of March 1, 2022.

Exhibit 10.28 WAIVER AND SECONDAMENDMENT TO LOAN AND SECURITYAGREEMENT This Waiver and Second Amendmentto Loan and Security Agreement(this ?Amendment?) is entered into this 1st day of March, 2022, by and between SILICON VALLEY BANK (?Bank?) and VERRICA PHARMACEUTICALS INC.,a Delaware corporation (?Borrower?), whose address is 44 West Gay Street, Suite 400, West Chester, Pennsylvania 19380. RECITAL

35 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

35 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Amended and Restated Non-Employee Director Compensation Policy, adopted by the Board as of February 24, 2022

Exhibit 10.27 VERRICA PHARMACEUTICALS INC. Amended and Restated Non-Employee Director Compensation Policy As adopted by the Board on February 24, 2022 Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of Verrica Pharmaceuticals Inc. (the ?Company?) and is not affiliated with an entity that beneficially owns 5% or more of the Company?s outstanding shares (ea

Waiver and Second Amendment to Mezzanine Loan and Security Agreement, dated as of March 1, 2022

Exhibit 10.26 WAIVER AND SECONDAMENDMENT TO MEZZANINE LOAN AND SECURITYAGREEMENT This Waiver and Second Amendment to Loan and Security Agreement(this ?Amendment? ) is entered into this 1st day of March,2022 by and among (a) SILICONVALLEY BANK, a California corporation (?SVB?), in its capacity as administrative agent and collateral agent (?Agent?), (b) SILICON VALLEY BANK, a California corporation,

Employment Agreement by and between the Registrant and Gary Goldenberg, dated as of August 1, 2020 (incorporated herein by reference to Exhibit 10.23 to the Registrant’s Annual Report on Form 10-K (File No. 001-38529), filed with the Securities and Exchange Commission on March 2, 2022).

DocuSign Envelope ID: 803EFDF1-1C49-48EE-B37C-C15EAF13DF96 Exhibit 10-23 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective August 1, 2020 (the ?Effective Date?), by and between Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results NDA for VP-102 for the treatment of molluscum assigned a PDUFA date of May 24, 2022 Company expects to dose first patient in Phase 2 trial of LTX-315 in basal cell ca

Exhibit 99.1 Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results NDA for VP-102 for the treatment of molluscum assigned a PDUFA date of May 24, 2022 Company expects to dose first patient in Phase 2 trial of LTX-315 in basal cell carcinoma in the first quarter of 2022 WEST CHESTER, PA ? March 2, 2022 (GLOBE NEWSWIRE) ? Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq:

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

Employment Agreement, by and between the Registrant and Christopher Hayes, dated as of February 27, 2020 (incorporated herein by reference to Exhibit 10.24 to the Registrant’s Annual Report on Form 10-K (File No. 001-38529), filed with the Securities and Exchange Commission on March 2, 2022).

Exhibit 10.24 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective February 27, 2020 (the ?Effective Date?), by and between Verrica Pharmaceuticals Inc., a Delaware corporation (the ?Company?) and Christopher G. Hayes (the ?Employee?). Whereas, the Company desires to continue to employ the Employee in the capacity of full-time Chief Legal Officer pursuant to t

VRCA / Verrica Pharmaceuticals Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92511W108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

AGREEMENT

EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them.

JOINT FILING AGREEMENT

Paul B. Manning SC 13G/A Exhibit A EXHIBIT A JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13D is being filed on behalf of each of the undersigned. February 14, 2022 /s/ Paul B. Manning Paul B. Manning BKB Growth Investments, LLC By Tiger Lily Capital, LLC, its manager By

VRCA / Verrica Pharmaceuticals Inc / Manning Paul B - AMENDMENT TO FORM SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 3)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 9251 1W 108 (CUSIP Number) December

JOINT FILING AGREEMENT

CUSIP No. 92511W108 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Common Stock, par value $0.0001 per share, of Verrica Pharmaceuticals Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under

VRCA / Verrica Pharmaceuticals Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No.

VRCA / Verrica Pharmaceuticals Inc / Davidson Matt - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ?240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ?240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securiti

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Com

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Com

Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal est

Company Overview November 29, 2021 Copyright ? 2021 Verrica Pharmaceuticals. All rights reserved. Exhibit 99.1 Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica?s own internal estimates and research. While Verrica beli

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility’s identified deficiencies from the FDA Verrica is engaging with the FDA on next

Exhibit 99.1 Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility?s identified deficiencies from the FDA Verrica is engaging with the FDA on next steps toward potential approval of VP-102 for the treatment of molluscum contagiosum WEST CHESTER, PA ? November 12, 2021 (GLOBE NEWSWIRE

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Com

Employment Agreement, by and between the Registrant and P. Terence Kohler, dated as of July 16, 2021 (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38529), filed with the Securities and Exchange Commission on November 11, 2021).

Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective July 16, 2021 (the ?Effective Date?), by and between Verrica Pharmaceuticals Inc., a Delaware corporation (the ?Company?) and Terry Kohler (the ?Employee?). Company and Employee are each herein referred to individually as a ?Party,? or collectively as the ?Parties?). Whereas, the Company desires

Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal est

Company Overview September 28, 2021 Copyright ? 2021 Verrica Pharmaceuticals. All rights reserved. Exhibit 99.1 Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica?s own internal estimates and research. While Verrica bel

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Co

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Co

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commi

Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

Exhibit 99.1 Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results WEST CHESTER, PA ? August 10, 2021 (GLOBE NEWSWIRE) ? Verrica Pharmaceuticals Inc. (?Verrica?) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021. ?This quarter, we c

Amended and Restated Non-Employee Director Compensation Policy (filed herewith).

EXHIBIT 10.1 VERRICA PHARMACEUTICALS INC. Amended and Restated NON-EMPLOYEE DIRECTOR COMPENSATION POLICY As adopted by the Board on March 1, 2021 Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of Verrica Pharmaceuticals Inc. (the ?Company?) and is not affiliated with an entity that beneficially owns 5% or more of the Company?s outstanding shares (each su

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissi

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum – Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 –

Exhibit 99.1 Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum ? Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 ? WEST CHESTER, PA ? May 28, 2021 (GLOBE NEWSWIRE) ? Verrica Pharmaceuticals Inc. (?Verrica?) (Nasdaq: VRCA), a dermatology therapeutics company developing med

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissi

Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results – Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 – – Raised

Exhibit 99.1 Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results ? Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 ? ? Raised approximately $30 million, before offering expenses, in an underwritten public offering ? ? Granted Torii Pharmaceutical Co., Ltd. an exc

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Collaboration and License Agreement, by and between the Company and Torii Pharmaceutical Co., Ltd., dated March 17, 2021 (incorporated herein by reference to exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38529), filed with the Securities and Exchange Commission on May 7, 2021).

Execution Copy Confidential CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED EXHIBIT 10.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commissio

- S-8

As filed with the Securities and Exchange Commission on May 7, 2021 Registration No.

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

- DEF 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 Verrica Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 001-38529 46-3137900 (State or other jurisdiction of incorporation) (Commis

Verrica Announces Pricing of Public Offering of Common Stock

Exhibit 99.2 Verrica Announces Pricing of Public Offering of Common Stock WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) ? Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of its underwritten public offering of 2,033,899 shares of its common stock at a

Underwriting Agreement by and among Verrica Pharmaceuticals Inc., Jefferies LLC, Cowen and Company, LLC and RBC Capital Markets, LLC, dated March 22, 2021.

Exhibit 1.1 Execution Version VERRICA PHARMACEUTICALS INC. (a Delaware corporation) 2,033,899 Shares of Common Stock UNDERWRITING AGREEMENT Dated: March 22, 2021 Verrica Pharmaceuticals Inc. (a Delaware corporation) 2,033,899 Shares of Common Stock UNDERWRITING AGREEMENT March 22, 2021 Jefferies LLC Cowen and Company, LLC RBC Capital Markets, LLC c/o Jefferies LLC 520 Madison Avenue New York, New

Verrica Announces Proposed Public Offering of Common Stock

EX-99.1 Exhibit 99.1 Verrica Announces Proposed Public Offering of Common Stock West Chester, Pa., March 22, 2021 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an

2,033,899 Shares Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-237171 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 25, 2020) 2,033,899 Shares Common Stock We are offering 2,033,899 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “VRCA.” The last reported sale price of our common stock on The Nasdaq Global Market on March 19, 20

Shares Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-237171 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to

First Amendment to Loan and Security Agreement, by and between the Company and Silicon Valley Bank, dated as of October 26, 2020.

Exhibit 10.21 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED FIRST Amendment to Loan and security agreement This First Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 26th day of October, 2020, by and between SILICO

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commis

First Amendment to Mezzanine Loan and Security Agreement, by and among the Company, Silicon Valley Bank and WestRiver Innovation Lending Fund VIII, L.P., dated as of October 26, 2020.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Exhibit 10.

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38529 Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results – FDA accepts resubmitted NDA for VP-102 for the treatment of molluscum contagiosum with PDUFA goal date of June 23, 2021 – – Verrica Announces Torii Pharmaceutical H

Exhibit 99.1 Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results ? FDA accepts resubmitted NDA for VP-102 for the treatment of molluscum contagiosum with PDUFA goal date of June 23, 2021 ? ? Verrica Announces Torii Pharmaceutical Has Exercised Option to Acquire Exclusive License Agreement to Develop and Commercialize VP-102 in Japan Triggering 60-Day Period to Final

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Clas

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92511W108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Com

Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum - PDUFA goal date assigned is June 23, 2021 – - VP-102 (cantharidin 0.7% Topical Solution) could potenti

Exhibit 99.1 Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum - PDUFA goal date assigned is June 23, 2021 ? - VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 mi

AGREEMENT

EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 16, 2021 PERCEPTIVE ADVISORS LLC

Joint Filing Agreement

Paul B. Manning SC 13G/A Exhibit A Joint Filing Agreement The undersigned hereby agree that this Schedule 13G (the ?Schedule 13G?) with respect to the common stock of Verrica Pharmaceuticals Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Clas

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92511W108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 2)* Verrica

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 2)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 9251 1W 108 (CUSIP Number) December 31

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 2)* Verrica

SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 2)* Verrica Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 9251 1W 108 (CUSIP Number) De

Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Commi

Disclaimer Certain information contained in this presentation and statements made orally The information in this presentation, including without limitation the forward- during this presentation relates to or is based on studies, publications, surveys

EX-99.1 Exhibit 99.1 Company Overview January 2021 1Exhibit 99.1 Company Overview January 2021 1 Disclaimer Certain information contained in this presentation and statements made orally The information in this presentation, including without limitation the forward- during this presentation relates to or is based on studies, publications, surveys looking statements contained herein, represent our v

Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2020 Verrica Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38529 46-3137900 (State or Other Jurisdiction of Incorporation) (Com